{"id":"https://openalex.org/W7207969369","doi":null,"title":"Baseline interleukin-6 is a prognostic factor for patients with metastatic breast cancer treated with eribulin","display_name":"Baseline interleukin-6 is a prognostic factor for patients with metastatic breast cancer treated with eribulin","publication_year":null,"publication_date":null,"ids":{"openalex":"https://openalex.org/W7207969369"},"language":"en","primary_location":{"id":"pmh:oai:irdb.nii.ac.jp:01354:0006298114","doi":null,"is_oa":true,"landing_page_url":"https://huhs.repo.nii.ac.jp/records/2000125","pdf_url":"https://huhs.repo.nii.ac.jp/record/2000125/files/1043_%E5%85%A8%E6%96%87.pdf","source":{"id":"https://openalex.org/S7407056385","display_name":"Institutional Repositories DataBase (IRDB)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I184597095","host_organization_name":"National Institute of Informatics","host_organization_lineage":["https://openalex.org/I184597095"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"doctoral thesis"},"volume":null,"type":"dissertation","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://huhs.repo.nii.ac.jp/record/2000125/files/1043_%E5%85%A8%E6%96%87.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5043487782","display_name":"Ayako Bun","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"\u6587, \u4e9c\u4e5f\u5b50","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5043487782"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.5644999742507935,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.5644999742507935,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.21940000355243683,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11313","display_name":"Immune cells in cancer","score":0.06870000064373016,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/interleukin-6","display_name":"interleukin-6","score":0.9620000123977661},{"id":"https://openalex.org/keywords/metastatic-breast-cancer","display_name":"metastatic breast cancer","score":0.9549999833106995},{"id":"https://openalex.org/keywords/eribulin","display_name":"eribulin","score":1.0},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.9049999713897705},{"id":"https://openalex.org/keywords/tumor-immune-microenvironment","display_name":"tumor immune microenvironment","score":0.8579999804496765},{"id":"https://openalex.org/keywords/myeloid-derived-suppressor-cells","display_name":"myeloid-derived suppressor cells","score":0.9990000128746033},{"id":"https://openalex.org/keywords/regulatory-t-cells","display_name":"regulatory T cells","score":0.8500000238418579},{"id":"https://openalex.org/keywords/cd8-t-cells","display_name":"CD8+ T cells","score":0.8519999980926514},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.7879999876022339},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9660000205039978},{"id":"https://openalex.org/keywords/anticancer-drug-response","display_name":"anticancer drug response","score":0.5120000243186951}],"concepts":[{"id":"https://openalex.org/C2776387010","wikidata":"https://www.wikidata.org/wiki/Q408717","display_name":"Eribulin","level":5,"score":0.9215999841690063},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8790000081062317},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6956999897956848},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.6876999735832214},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6766999959945679},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.6442999839782715},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.46129998564720154},{"id":"https://openalex.org/C3019894029","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Overall survival","level":2,"score":0.40130001306533813},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.39149999618530273},{"id":"https://openalex.org/C553184892","wikidata":"https://www.wikidata.org/wiki/Q1141429","display_name":"Flow cytometry","level":2,"score":0.3472000062465668},{"id":"https://openalex.org/C63363279","wikidata":"https://www.wikidata.org/wiki/Q5133848","display_name":"Clinical significance","level":2,"score":0.3425000011920929},{"id":"https://openalex.org/C2778690821","wikidata":"https://www.wikidata.org/wiki/Q212354","display_name":"Cytokine","level":2,"score":0.3321000039577484},{"id":"https://openalex.org/C154317977","wikidata":"https://www.wikidata.org/wiki/Q376266","display_name":"Cytotoxic T cell","level":3,"score":0.31929999589920044},{"id":"https://openalex.org/C74172505","wikidata":"https://www.wikidata.org/wiki/Q194908","display_name":"Interleukin","level":3,"score":0.31859999895095825},{"id":"https://openalex.org/C2779013556","wikidata":"https://www.wikidata.org/wiki/Q181876","display_name":"Metastasis","level":3,"score":0.27900001406669617},{"id":"https://openalex.org/C164027704","wikidata":"https://www.wikidata.org/wiki/Q3491837","display_name":"Proinflammatory cytokine","level":3,"score":0.2745000123977661},{"id":"https://openalex.org/C156730664","wikidata":"https://www.wikidata.org/wiki/Q23308590","display_name":"Interleukin 23","level":4,"score":0.2741999924182892},{"id":"https://openalex.org/C2777371288","wikidata":"https://www.wikidata.org/wiki/Q410130","display_name":"Interleukin 2","level":3,"score":0.2732999920845032},{"id":"https://openalex.org/C50382708","wikidata":"https://www.wikidata.org/wiki/Q223218","display_name":"Proportional hazards model","level":2,"score":0.27140000462532043},{"id":"https://openalex.org/C194409129","wikidata":"https://www.wikidata.org/wiki/Q103824","display_name":"Hematology","level":2,"score":0.2687000036239624},{"id":"https://openalex.org/C10515644","wikidata":"https://www.wikidata.org/wiki/Q543310","display_name":"Survival analysis","level":2,"score":0.26750001311302185},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.26739999651908875},{"id":"https://openalex.org/C179185449","wikidata":"https://www.wikidata.org/wiki/Q219699","display_name":"Suppressor","level":3,"score":0.2662000060081482},{"id":"https://openalex.org/C2776907518","wikidata":"https://www.wikidata.org/wiki/Q1734165","display_name":"Performance status","level":3,"score":0.26429998874664307},{"id":"https://openalex.org/C11988809","wikidata":"https://www.wikidata.org/wiki/Q412889","display_name":"Interleukin 6","level":3,"score":0.25369998812675476},{"id":"https://openalex.org/C17991360","wikidata":"https://www.wikidata.org/wiki/Q21173843","display_name":"Tumor necrosis factor alpha","level":2,"score":0.2529999911785126},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.25290000438690186}],"mesh":[],"locations_count":1,"locations":[{"id":"pmh:oai:irdb.nii.ac.jp:01354:0006298114","doi":null,"is_oa":true,"landing_page_url":"https://huhs.repo.nii.ac.jp/records/2000125","pdf_url":"https://huhs.repo.nii.ac.jp/record/2000125/files/1043_%E5%85%A8%E6%96%87.pdf","source":{"id":"https://openalex.org/S7407056385","display_name":"Institutional Repositories DataBase (IRDB)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I184597095","host_organization_name":"National Institute of Informatics","host_organization_lineage":["https://openalex.org/I184597095"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"doctoral thesis"}],"best_oa_location":{"id":"pmh:oai:irdb.nii.ac.jp:01354:0006298114","doi":null,"is_oa":true,"landing_page_url":"https://huhs.repo.nii.ac.jp/records/2000125","pdf_url":"https://huhs.repo.nii.ac.jp/record/2000125/files/1043_%E5%85%A8%E6%96%87.pdf","source":{"id":"https://openalex.org/S7407056385","display_name":"Institutional Repositories DataBase (IRDB)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I184597095","host_organization_name":"National Institute of Informatics","host_organization_lineage":["https://openalex.org/I184597095"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"doctoral thesis"},"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[{"id":"https://openalex.org/G5680689147","display_name":"Development of biomarkers and new treatments for metastatic breast cancer by eribulin","funder_award_id":"22K08764","funder_id":"https://openalex.org/F4320334764","funder_display_name":"Japan Society for the Promotion of Science"},{"id":"https://openalex.org/G6053205675","display_name":"Complementary cellular regulatory mechanisms of TP53 and lipid molecules in triple negative breast cancer","funder_award_id":"21K19522","funder_id":"https://openalex.org/F4320334764","funder_display_name":"Japan Society for the Promotion of Science"}],"funders":[{"id":"https://openalex.org/F4320334764","display_name":"Japan Society for the Promotion of Science","ror":"https://ror.org/00hhkn466"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7207969369.pdf","grobid_xml":"https://content.openalex.org/works/W7207969369.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3131569603","https://openalex.org/W3092402059","https://openalex.org/W2587897384","https://openalex.org/W2482139082","https://openalex.org/W7129526245","https://openalex.org/W2586608125","https://openalex.org/W4396590949","https://openalex.org/W3013300349","https://openalex.org/W4387931614","https://openalex.org/W3009691144"],"abstract_inverted_index":{"Purpose:":[0],"Eribulin":[1],"is":[2,194,211,229],"a":[3,240],"unique":[4],"anti-cancer":[5],"drug":[6],"which":[7,218],"can":[8],"improve":[9],"overall":[10],"survival":[11,102,137],"(OS)":[12],"of":[13,28,37,40,95,216],"patients":[14,46,82,128,182,200,234],"with":[15,48,83,86,129,141,143,183,189,201,204,213,235],"metastatic":[16],"breast":[17],"cancer":[18],"(MBC),":[19],"probably":[20],"by":[21,121],"modulating":[22],"the":[23,34,52,78,119],"tumor":[24,242],"immune":[25,57,79,243],"microenvironment.The":[26],"aim":[27],"this":[29,91],"study":[30],"was":[31,105,161],"to":[32,71,100,187,239],"investigate":[33],"clinical":[35],"significance":[36],"serum":[38],"levels":[39,115,215],"immune-related":[41],"and":[42,56,65,67,103,107,111,138,149,154,176],"inflammatory":[43],"cytokines":[44,55,75],"in":[45,118,181,199,233],"treated":[47,85,203],"eribulin.Furthermore,":[49],"we":[50],"investigated":[51],"association":[53],"between":[54],"cells,":[58,70],"such":[59,222],"as":[60,223],"myeloid-derived":[61],"suppressor":[62],"cells":[63],"(MDSCs)":[64],"cytotoxic":[66],"regulatory":[68,112],"T":[69,113],"explore":[72],"how":[73],"these":[74],"might":[76],"affect":[77],"microenvironment.Methods:":[80],"Sixty-eight":[81],"MBC":[84,202],"eribulin":[87,228],"were":[88,116,173,178],"recruited":[89],"for":[90,166],"retrospective":[92],"study.The":[93],"relationship":[94],"cytokines,":[96],"including":[97],"interleukin":[98],"(IL)-6,":[99],"progression-free":[101],"OS":[104,139,167],"examined.CD4+":[106],"CD8+":[108,171,224],"lymphocyte,":[109],"MDSC":[110],"cell":[114],"determined":[117],"blood":[120],"flow":[122],"cytometry":[123],"analysis.Results:":[124],"In":[125],"our":[126],"cohort,":[127],"high":[130,184,209,236],"IL-6":[131,145,160,193,210,237],"at":[132],"baseline":[133,159],"had":[134],"shorter":[135],"progressionfree":[136],"compared":[140,186],"those":[142,188],"low":[144,190],"(p":[146,168],"=":[147,151,169],"0.0017":[148],"p":[150],"0.0012,":[152],"respectively).Univariable":[153],"multivariable":[155],"analyses":[156],"revealed":[157],"that":[158,208,227],"an":[162,195],"independent":[163],"prognostic":[164,197],"factor":[165,198],"0.0058).Importantly,":[170],"lymphocytes":[172],"significantly":[174,179],"lower":[175],"MDSCs":[177,217],"higher":[180,214],"IL-6,":[185],"IL-6.":[191],"Conclusion:Baseline":[192],"important":[196],"eribulin.Our":[205],"results":[206],"show":[207],"associated":[212],"suppress":[219],"anti-tumor":[220],"immunity,":[221],"cells.It":[225],"appears":[226],"not":[230],"particularly":[231],"effective":[232],"due":[238],"poor":[241],"microenvironment.":[244]},"counts_by_year":[],"updated_date":"2026-10-12T09:40:04.860316","created_date":"2026-09-04T00:00:00"}